Sanofi will make key regulatory submissions in 2018 aimed at bringing its immuno-oncology portfolio up to speed; the company's head of oncology development Joanne Lager tells Scrip about the company's PD-1 strategy and promising early-stage R&D candidates.
Sanofi is not a top player in the IO market, having fallen behind the likes of Merck & Co. Inc., Bristol-Myers Squibb Co. and Roche, which have...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?